A5081667215- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Glioma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- CRISPR and Genetic Engineering
- Gastric Cancer Management and Outcomes
- Cancer Research and Treatments
- Estrogen and related hormone effects
- Pancreatic and Hepatic Oncology Research
- Renal and related cancers
- Advanced biosensing and bioanalysis techniques
- Advanced Breast Cancer Therapies
- Cancer-related molecular mechanisms research
- Biosensors and Analytical Detection
- Hepatocellular Carcinoma Treatment and Prognosis
- Breast Cancer Treatment Studies
- PI3K/AKT/mTOR signaling in cancer
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Renal cell carcinoma treatment
- Single-cell and spatial transcriptomics
- Fibroblast Growth Factor Research
- Brain Metastases and Treatment
Inserm
2015-2024
Université de Rouen Normandie
2015-2024
Normandie Université
2017-2024
Institute for Research and Innovation in Biomedicine
2016-2023
Centre Henri Becquerel
2015-2023
Institut de Recherche et d’Innovation
2022
Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2016-2022
Génomique du cancer et du cerveau
2022
Centre Hospitalier Universitaire de Rouen
2022
Humanitas University
2015
The direct comparison of CA19.9, circulating tumour cells (CTCs) and DNA (ctDNA) using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has never been performed for the diagnosis solid pancreatic tumours (SPTs).We included 68 patients with a SPT referred EUS-FNA. CTCs were analysed size-based platform ctDNA digital PCR. sensitivity, specificity, negative positive predictive values evaluated each marker their combination.SPTs corresponded to 58 malignant (52 adenocarcinoma (PA) 6...
// Florian Clatot 1,2,3 , Anne Perdrix 3,4 Laetitia Augusto 1 Ludivine Beaussire 3,5 Julien Delacour Céline Calbrix 4 David Sefrioui 3,5,6 Pierre-Julien Viailly 2 Michael Bubenheim 7 Cristian Moldovan Cristina Alexandru Isabelle Tennevet Olivier Rigal Cécile Guillemet Marianne Leheurteur Sophie Gouérant Camille Petrau 1,3 Jean-Christophe Théry 1,5 Jean-Michel Picquenot 1,2,4 Corinne Veyret Thierry Frébourg 5 Fabrice Jardin Nasrin Sarafan-Vasseur 3,5,* and Frédéric Di Fiore 1,3,5,6,*...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous malignancy harboring frequent targetable activating somatic mutations. Emerging evidence suggests that circulating cell-free DNA (cfDNA) can be used to detect variants in DLBCL using Next-Generation Sequencing (NGS) experiments. In this proof-of-concept study, we chose develop simple valuable digital PCR (dPCR) assays for the detection of recurrent exportin-1 (XPO1) E571K, EZH2 Y641N, MYD88 L265P mutations patients,...
Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence at end adjuvant treatment by AI early cancer had never been clearly established. In this context, aim present study was evaluate mutation frequency and after relapse. This monocentric retrospective based on available stored plasmas included all patients who completed least 2 years experienced a documented relapse their treatment....
Reverse transcription-quantitative PCR on nasopharyngeal swabs is currently the reference COVID-19 diagnosis method but exhibits imperfect sensitivity.We developed a multiplex reverse transcription-digital droplet (RT-ddPCR) assay, targeting 6 SARS-CoV-2 genomic regions, and evaluated it saliva samples collected from 130 positive or negative ambulatory individuals, who presented symptoms suggestive of mild moderate SARS-CoV2 infection.For swab samples, results obtained using 6-plex RT-ddPCR...
Abstract The clinical implications of plasmatic cell-free and tumor DNA (cfDNA ctDNA) are challenging in glioblastoma. This prospective study included 52 consecutive newly diagnosed glioblastoma (n = 49) or gliosarcoma 3) patients treated with concomitant temozolomide radiotherapy (RT-TMZ), followed by a TMZ maintenance phase. Plasma samples were collected at baseline, before RT-TMZ (pre-RT-TMZ) the end adjuvant TMZ, time progression cases progressive disease (PD). cfDNA concentration was...
Abstract Background Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting. We aimed prospectively compare the risk of early according circulating ESR1 mutations, CA-15.3, and cell-free DNA MBC patients treated with aromatase inhibitor (AI). Methods Patients AI were included. Circulating assessment was performed every 3 months. The primary...
Secretory carcinoma (SC) is characterized by ETV6 rearrangements, most often ETV6-NTRK3 fusion. Given its histologic overlap with other salivary gland tumors (SGTs), SCs can be difficult to diagnose without genetic confirmation. A recently developed pan-TRK (tropomyosin receptor kinase) antibody shows promise for identifying NTRK (neurotrophic tyrosine kinase 3) fusions. The aim of this study was evaluate the utility immunohistochemistry in distinguishing from mimics and selecting patients...
Circulating cell-free DNA (ccfDNA) bears great promise as biomarker for personalized medicine, but ccfDNA is present only at low levels in the plasma or serum of cancer patients. E-ice-COLD-PCR a recently developed enrichment method to detect and identify mutations low-abundance clinical samples. However, recent studies have shown importance accurately quantify clinically important decisions will depend on certain mutation thresholds. The possibility an remains point concern might limit its...
Rare copy number variations (CNVs) are a major cause of genetic diseases. Simple targeted methods required for their confirmation and segregation analysis. We developed simple universal CNV assay based on digital PCR (dPCR) locked nucleic acid (LNA) hydrolysis probes.We analyzed the mapping 90 LNA probes from Roche Universal ProbeLibrary (UPL). For each CNV, selection optimal primers probe was almost automated; were reused across assays dPCR included amplicon reference amplicon. assessed...
Abstract Epidermal growth factor receptor ( EGFR ) amplification and variant III EGFRvIII , deletion of exons 2–7) are clinical interest for glioblastoma. The aim was to develop a digital PCR (dPCR)-based method using locked nucleic acid (LNA)-based hydrolysis probes, allowing the simultaneous detection variant. Sixty-two patients were included. An exploratory cohort n = 19) used dPCR assay three selected amplicons within gene, targeting intron 1 (EGFR1), junction exon 3 (EGFR2) 22 (EGFR3)....
Abstract Transarterial chemoembolization (TACE) is used to treat patients with unresectable hepatocellular carcinoma (HCC). We evaluated the clinical impact of a‐fetoprotein (AFP) and circulating cell‐free tumor DNA (cfDNA ctDNA) changes around TACE procedure. Our prospective monocentric study enrolled consecutive treated TACE, samples collected at baseline (D − 1), Day 2 + 2) 1 month (M 1) after TACE. cfDNA was quantified by fluorometric method, ctDNA digital polymerase chain reaction...
Endocrine therapy is frequently administered in patients with hormone dependent (HR+) metastatic endometrial cancer. ESR1 mutations have emerged as a key mechanism of aromatase inhibitor (AI) resistance HR + breast cancer and can be monitored using circulating tumor DNA (ctDNA). The aim this study was to explore the incidence clinical relevance treated by AI or megestrol acetate (M) for advanced carcinoma.This single-center retrospective performed at Henri Becquerel Center (Rouen) looked...
Objective: To investigate in patients treated for a resectable pancreatic ductal adenocarcinoma [pancreatic (PA)], the prognostic value of baseline carbohydrate antigen 19.9 (CA19-9) and circulating tumor DNA (ctDNA) overall survival (OS), to improve death risk stratification, based on planned ancillary study from PANACHE01–PRODIGE 48 trial. Background: Biological borderline situation that was first used by MD Anderson, became standard practice following international consensus conference...
We conducted a prospective study to assess the prognostic impact of selected copy number variations (CNVs) in Stage II-III microsatellite stable (MSS) colon cancer. A total 401 patients were included from 01/2004 01/2009. The CNVs 8 target genes, DCC/18q, EGFR/7p, TP53/17p, BLK/8p, MYC/8q, APC/5q, ERBB2/17q and STK6/20q, detected using quantitative multiplex polymerase chain reaction short fluorescent fragment (QMPSF) method. primary end-point was on 4-year disease-free survival (DFS)....
Molecular factors influence relapse patterns in glioblastoma. The hotspot mutation located at position 289 of the extracellular domain epidermal growth factor receptor (EGFRA289mut) is associated with a more infiltrative phenotype. primary objective this study was to explore impact EGFRA289 on pattern after chemoradiotherapy-based treatment patients suffering from newly diagnosed glioblastoma.An ancillary prospective cohort glioblastoma conducted. All received radiotherapy and concomitant...
Breast cancer is a frequent disease for which the discovery of markers that enable early detection or prognostic assessment remains challenging. Circular RNAs (circRNAs) are single-stranded structures in closed loops produced by backsplicing. CircRNA and messenger RNA (mRNA) generated co-transcriptionally, backsplicing linear splicing compete against each other. As mRNAs key players tumorigenesis, we hypothesize disruption balance between circRNAs could promote breast cancer. Hence,...